Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Takács, Ferenc, Kotmayer, Lili, Czeti, Ágnes, Szalóki, Gábor, László, Tamás, Mikala, Gábor, Márk, Ágnes, Masszi, András, Farkas, Péter, Plander, Márk, Weisinger, Júlia, Demeter, Judit, Fekete, Sándor, Szerafin, László, Deák, Beáta Margit, Szaleczky, Erika, Sulák, Adrienn, Borbényi, Zita, Barna, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532522/
https://www.ncbi.nlm.nih.gov/pubmed/36213161
http://dx.doi.org/10.3389/pore.2022.1610659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532522/
https://www.ncbi.nlm.nih.gov/pubmed/36213161
http://dx.doi.org/10.3389/pore.2022.1610659

Ejemplares similares